Cargando…

The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report

BACKGROUND: Myeloid sarcoma (MS) is a very rare condition, develops both in patients with other hematological neoplasms, and as isolated tumor. MS of the gynecologic tract is extremely rare. An available literature data about diagnosis and management of MS is summarized in the article. The role of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Shatilova, Aleksina, Girshova, Larisa, Zaytsev, Daniil, Budaeva, Irina, Mirolyubova, Yuliya, Ryzhkova, Darya, Grozov, Roman, Bogdanov, Konstantin, Nikulina, Tatiana, Motorin, Dmitriy, Zammoeva, Darina, Efremova, Svetlana, Ivanov, Vladimir, Petukhov, Alexey, Alekseeva, Yuliya, Zaritskey, Andrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088676/
https://www.ncbi.nlm.nih.gov/pubmed/33933047
http://dx.doi.org/10.1186/s12905-021-01328-y
_version_ 1783686891490508800
author Shatilova, Aleksina
Girshova, Larisa
Zaytsev, Daniil
Budaeva, Irina
Mirolyubova, Yuliya
Ryzhkova, Darya
Grozov, Roman
Bogdanov, Konstantin
Nikulina, Tatiana
Motorin, Dmitriy
Zammoeva, Darina
Efremova, Svetlana
Ivanov, Vladimir
Petukhov, Alexey
Alekseeva, Yuliya
Zaritskey, Andrey
author_facet Shatilova, Aleksina
Girshova, Larisa
Zaytsev, Daniil
Budaeva, Irina
Mirolyubova, Yuliya
Ryzhkova, Darya
Grozov, Roman
Bogdanov, Konstantin
Nikulina, Tatiana
Motorin, Dmitriy
Zammoeva, Darina
Efremova, Svetlana
Ivanov, Vladimir
Petukhov, Alexey
Alekseeva, Yuliya
Zaritskey, Andrey
author_sort Shatilova, Aleksina
collection PubMed
description BACKGROUND: Myeloid sarcoma (MS) is a very rare condition, develops both in patients with other hematological neoplasms, and as isolated tumor. MS of the gynecologic tract is extremely rare. An available literature data about diagnosis and management of MS is summarized in the article. The role of chemotherapy, radiation therapy, surgery and bone marrow transplantation in the treatment is discussed. Polychemotherapy and allogeneic bone marrow transplantation were suggested to be the optimal treatment strategy of MS of the gynecological tract. The use of new targeted agents results in promising clinical data. CASE PRESENTATION: We are presenting a rare clinical case of a MS of the uterine cervix with concomitant bone marrow involvement and describe all the peculiarities of the clinical course, diagnosis, and treatment. The patient received chemotherapy followed by allogeneic bone marrow transplantation. The pre-transplant therapy allowed us to perform allogeneic bone marrow transplantation with the deepest response possible: complete PET-negative and MRD-negative remission of the disease. CONCLUSIONS: MS remains a subject of discussion regarding its diagnostic and therapeutic aspects. The use of novel targeting agents can be perspective option for patient with extramedullary disease.
format Online
Article
Text
id pubmed-8088676
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80886762021-05-03 The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report Shatilova, Aleksina Girshova, Larisa Zaytsev, Daniil Budaeva, Irina Mirolyubova, Yuliya Ryzhkova, Darya Grozov, Roman Bogdanov, Konstantin Nikulina, Tatiana Motorin, Dmitriy Zammoeva, Darina Efremova, Svetlana Ivanov, Vladimir Petukhov, Alexey Alekseeva, Yuliya Zaritskey, Andrey BMC Womens Health Case Report BACKGROUND: Myeloid sarcoma (MS) is a very rare condition, develops both in patients with other hematological neoplasms, and as isolated tumor. MS of the gynecologic tract is extremely rare. An available literature data about diagnosis and management of MS is summarized in the article. The role of chemotherapy, radiation therapy, surgery and bone marrow transplantation in the treatment is discussed. Polychemotherapy and allogeneic bone marrow transplantation were suggested to be the optimal treatment strategy of MS of the gynecological tract. The use of new targeted agents results in promising clinical data. CASE PRESENTATION: We are presenting a rare clinical case of a MS of the uterine cervix with concomitant bone marrow involvement and describe all the peculiarities of the clinical course, diagnosis, and treatment. The patient received chemotherapy followed by allogeneic bone marrow transplantation. The pre-transplant therapy allowed us to perform allogeneic bone marrow transplantation with the deepest response possible: complete PET-negative and MRD-negative remission of the disease. CONCLUSIONS: MS remains a subject of discussion regarding its diagnostic and therapeutic aspects. The use of novel targeting agents can be perspective option for patient with extramedullary disease. BioMed Central 2021-05-01 /pmc/articles/PMC8088676/ /pubmed/33933047 http://dx.doi.org/10.1186/s12905-021-01328-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Shatilova, Aleksina
Girshova, Larisa
Zaytsev, Daniil
Budaeva, Irina
Mirolyubova, Yuliya
Ryzhkova, Darya
Grozov, Roman
Bogdanov, Konstantin
Nikulina, Tatiana
Motorin, Dmitriy
Zammoeva, Darina
Efremova, Svetlana
Ivanov, Vladimir
Petukhov, Alexey
Alekseeva, Yuliya
Zaritskey, Andrey
The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report
title The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report
title_full The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report
title_fullStr The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report
title_full_unstemmed The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report
title_short The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report
title_sort myeloid sarcoma treated by venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088676/
https://www.ncbi.nlm.nih.gov/pubmed/33933047
http://dx.doi.org/10.1186/s12905-021-01328-y
work_keys_str_mv AT shatilovaaleksina themyeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT girshovalarisa themyeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT zaytsevdaniil themyeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT budaevairina themyeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT mirolyubovayuliya themyeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT ryzhkovadarya themyeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT grozovroman themyeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT bogdanovkonstantin themyeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT nikulinatatiana themyeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT motorindmitriy themyeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT zammoevadarina themyeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT efremovasvetlana themyeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT ivanovvladimir themyeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT petukhovalexey themyeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT alekseevayuliya themyeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT zaritskeyandrey themyeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT shatilovaaleksina myeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT girshovalarisa myeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT zaytsevdaniil myeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT budaevairina myeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT mirolyubovayuliya myeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT ryzhkovadarya myeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT grozovroman myeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT bogdanovkonstantin myeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT nikulinatatiana myeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT motorindmitriy myeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT zammoevadarina myeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT efremovasvetlana myeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT ivanovvladimir myeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT petukhovalexey myeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT alekseevayuliya myeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport
AT zaritskeyandrey myeloidsarcomatreatedbyvenetoclaxwithhypomethylatingagentfollowedbystemcelltransplantationrarecasereport